Vijay Pande Starts AI-Native Biotech Firm VZVC
Pande discusses biology's shift to engineering and his smaller investment approach at the new firm.
Vijay Pande departed a16z last year after leading its roughly four billion dollar biotech practice. He founded VZVC as a smaller AI-native venture firm. In a TechCrunch interview Pande describes biology moving from a discovery science to an engineering discipline. He also addresses clinical trial challenges and explains the decision to pursue fewer investments. The piece quotes him saying the firm is not doing thirty bets a year. The report frames VZVC as a focused operation built around artificial intelligence tools rather than the broad portfolio strategy he previously managed.
Combined views
84.1K
1 post, first seen 4d ago
Vijay Pande Starts AI-Native Biotech Firm VZVC
Pande discusses biology's shift to engineering and his smaller investment approach at the new firm.
Vijay Pande departed a16z last year after leading its roughly four billion dollar biotech practice. He founded VZVC as a smaller AI-native venture firm. In a TechCrunch interview Pande describes biology moving from a discovery science to an engineering discipline. He also addresses clinical trial challenges and explains the decision to pursue fewer investments. The piece quotes him saying the firm is not doing thirty bets a year. The report frames VZVC as a focused operation built around artificial intelligence tools rather than the broad portfolio strategy he previously managed.
Reactions
1 postTE 
TechCrunch@TechCrunchVijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally https://spr.ly/6018B12xCm
- likes: 260
- replies: 13
- bookmarks: 202
- reposts: 33